Role of imidazoline receptors in cardiovascular regulation
The involvement of nonadrenergic imidazoline specific receptors in the central control of the vasomotor tone and in the mechanism of action of drugs bearing an imidazoline structure, or analogs, is now well documented. Imidazoline-specific binding sites were found in many tissues and species. Moreov...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1994-12, Vol.74 (13), p.A3-A6 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A6 |
|---|---|
| container_issue | 13 |
| container_start_page | A3 |
| container_title | The American journal of cardiology |
| container_volume | 74 |
| creator | Dontenwill, M. Tibiriça, E. Greney, H. Bennaï, F. Feldman, J. Stutzmann, J. Bricca, G. Belcourt, A. Bousquet, P. |
| description | The involvement of nonadrenergic imidazoline specific receptors in the central control of the vasomotor tone and in the mechanism of action of drugs bearing an imidazoline structure, or analogs, is now well documented. Imidazoline-specific binding sites were found in many tissues and species. Moreover, until now, it is only in the brainstem that such binding sites are associated with a function: the hyportensive effect of imidazoline-like drugs. Rilmenidine, which is an oxazoline structurally related to the reference imidazolines, exerts a central hypotensive effect of central origin involving imidazoline receptors. The selectivity of rilmenidine for the imidazoline receptors compared to
α
2-adrenergic receptors could explain the low incidence of sedative side effects observed with this antihypertensive drug. A specific anti-imidazoline radioimmunoassay allowed us to detect the presence of an immunoreactive imidazoline-like substance in human sera. High levels of this immunoreactive substance are associated with high blood pressure in 20–30% of the hypertensive patients. This observation indicates that high levels of this immunoreactive substance in the serum can be associated with some kinds of primary hypertension. The cause-and-effect relation between these 2 phenomena has not yet been determined. This substance is in process of purification; it could be a candidate to be an endogenous ligand of the imidazoline receptors. |
| doi_str_mv | 10.1016/0002-9149(94)90035-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76888918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002914994900353</els_id><sourcerecordid>4486781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-bdbb9092d97243bac1294c4fc1dcc7a729768db3071fb671d853d682368e95e13</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMoOl7eQKGIiC6qOUmbiwtBxBsIgug6pEkqkU4zJq2gT2_GGWbhwtXh8H__4fAhtA_4DDCwc4wxKSVU8kRWpxJjWpd0DU1AcFmCBLqOJitkC22n9J5XgJptok0upagFmaCL59C5IrSFn3qrv0Pne1dEZ9xsCDEVvi-MjtaHT53M2OmYs7c8Bx_6XbTR6i65veXcQa-3Ny_X9-Xj093D9dVjaSqgQ9nYppFYEis5qWijDRBZmao1YI3hmhPJmbANxRzahnGwoqaWCUKZcLJ2QHfQ8eLuLIaP0aVBTX0yrut078KYVK4LIUFk8PAP-B7G2OffFKFZDzDGM1QtIBNDStG1ahb9VMcvBVjNvaq5NDWXpmSlfr0qmmsHy9tjM3V2VVqKzPnRMs-idNdG3RufVhilrCZ1nbHLBeaysE_vokrGu94467P0Qdng___jB0npkmk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230351667</pqid></control><display><type>article</type><title>Role of imidazoline receptors in cardiovascular regulation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dontenwill, M. ; Tibiriça, E. ; Greney, H. ; Bennaï, F. ; Feldman, J. ; Stutzmann, J. ; Bricca, G. ; Belcourt, A. ; Bousquet, P.</creator><creatorcontrib>Dontenwill, M. ; Tibiriça, E. ; Greney, H. ; Bennaï, F. ; Feldman, J. ; Stutzmann, J. ; Bricca, G. ; Belcourt, A. ; Bousquet, P.</creatorcontrib><description>The involvement of nonadrenergic imidazoline specific receptors in the central control of the vasomotor tone and in the mechanism of action of drugs bearing an imidazoline structure, or analogs, is now well documented. Imidazoline-specific binding sites were found in many tissues and species. Moreover, until now, it is only in the brainstem that such binding sites are associated with a function: the hyportensive effect of imidazoline-like drugs. Rilmenidine, which is an oxazoline structurally related to the reference imidazolines, exerts a central hypotensive effect of central origin involving imidazoline receptors. The selectivity of rilmenidine for the imidazoline receptors compared to
α
2-adrenergic receptors could explain the low incidence of sedative side effects observed with this antihypertensive drug. A specific anti-imidazoline radioimmunoassay allowed us to detect the presence of an immunoreactive imidazoline-like substance in human sera. High levels of this immunoreactive substance are associated with high blood pressure in 20–30% of the hypertensive patients. This observation indicates that high levels of this immunoreactive substance in the serum can be associated with some kinds of primary hypertension. The cause-and-effect relation between these 2 phenomena has not yet been determined. This substance is in process of purification; it could be a candidate to be an endogenous ligand of the imidazoline receptors.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/0002-9149(94)90035-3</identifier><identifier>PMID: 7998582</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; Cardiovascular disease ; Cardiovascular Physiological Phenomena ; Drug therapy ; Fundamental and applied biological sciences. Psychology ; Heart ; Humans ; Hypertension - blood ; Imidazoles - immunology ; Imidazoles - metabolism ; Imidazoline Receptors ; Medical research ; Receptors, Drug - immunology ; Receptors, Drug - physiology ; Vasomotor System - metabolism ; Vasomotor System - physiopathology ; Vertebrates: cardiovascular system</subject><ispartof>The American journal of cardiology, 1994-12, Vol.74 (13), p.A3-A6</ispartof><rights>1994</rights><rights>1995 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Dec 22, 1994</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-bdbb9092d97243bac1294c4fc1dcc7a729768db3071fb671d853d682368e95e13</citedby><cites>FETCH-LOGICAL-c413t-bdbb9092d97243bac1294c4fc1dcc7a729768db3071fb671d853d682368e95e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0002914994900353$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23911,23912,25120,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3365255$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7998582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dontenwill, M.</creatorcontrib><creatorcontrib>Tibiriça, E.</creatorcontrib><creatorcontrib>Greney, H.</creatorcontrib><creatorcontrib>Bennaï, F.</creatorcontrib><creatorcontrib>Feldman, J.</creatorcontrib><creatorcontrib>Stutzmann, J.</creatorcontrib><creatorcontrib>Bricca, G.</creatorcontrib><creatorcontrib>Belcourt, A.</creatorcontrib><creatorcontrib>Bousquet, P.</creatorcontrib><title>Role of imidazoline receptors in cardiovascular regulation</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>The involvement of nonadrenergic imidazoline specific receptors in the central control of the vasomotor tone and in the mechanism of action of drugs bearing an imidazoline structure, or analogs, is now well documented. Imidazoline-specific binding sites were found in many tissues and species. Moreover, until now, it is only in the brainstem that such binding sites are associated with a function: the hyportensive effect of imidazoline-like drugs. Rilmenidine, which is an oxazoline structurally related to the reference imidazolines, exerts a central hypotensive effect of central origin involving imidazoline receptors. The selectivity of rilmenidine for the imidazoline receptors compared to
α
2-adrenergic receptors could explain the low incidence of sedative side effects observed with this antihypertensive drug. A specific anti-imidazoline radioimmunoassay allowed us to detect the presence of an immunoreactive imidazoline-like substance in human sera. High levels of this immunoreactive substance are associated with high blood pressure in 20–30% of the hypertensive patients. This observation indicates that high levels of this immunoreactive substance in the serum can be associated with some kinds of primary hypertension. The cause-and-effect relation between these 2 phenomena has not yet been determined. This substance is in process of purification; it could be a candidate to be an endogenous ligand of the imidazoline receptors.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Physiological Phenomena</subject><subject>Drug therapy</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart</subject><subject>Humans</subject><subject>Hypertension - blood</subject><subject>Imidazoles - immunology</subject><subject>Imidazoles - metabolism</subject><subject>Imidazoline Receptors</subject><subject>Medical research</subject><subject>Receptors, Drug - immunology</subject><subject>Receptors, Drug - physiology</subject><subject>Vasomotor System - metabolism</subject><subject>Vasomotor System - physiopathology</subject><subject>Vertebrates: cardiovascular system</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUhoMoOl7eQKGIiC6qOUmbiwtBxBsIgug6pEkqkU4zJq2gT2_GGWbhwtXh8H__4fAhtA_4DDCwc4wxKSVU8kRWpxJjWpd0DU1AcFmCBLqOJitkC22n9J5XgJptok0upagFmaCL59C5IrSFn3qrv0Pne1dEZ9xsCDEVvi-MjtaHT53M2OmYs7c8Bx_6XbTR6i65veXcQa-3Ny_X9-Xj093D9dVjaSqgQ9nYppFYEis5qWijDRBZmao1YI3hmhPJmbANxRzahnGwoqaWCUKZcLJ2QHfQ8eLuLIaP0aVBTX0yrut078KYVK4LIUFk8PAP-B7G2OffFKFZDzDGM1QtIBNDStG1ahb9VMcvBVjNvaq5NDWXpmSlfr0qmmsHy9tjM3V2VVqKzPnRMs-idNdG3RufVhilrCZ1nbHLBeaysE_vokrGu94467P0Qdng___jB0npkmk</recordid><startdate>19941222</startdate><enddate>19941222</enddate><creator>Dontenwill, M.</creator><creator>Tibiriça, E.</creator><creator>Greney, H.</creator><creator>Bennaï, F.</creator><creator>Feldman, J.</creator><creator>Stutzmann, J.</creator><creator>Bricca, G.</creator><creator>Belcourt, A.</creator><creator>Bousquet, P.</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19941222</creationdate><title>Role of imidazoline receptors in cardiovascular regulation</title><author>Dontenwill, M. ; Tibiriça, E. ; Greney, H. ; Bennaï, F. ; Feldman, J. ; Stutzmann, J. ; Bricca, G. ; Belcourt, A. ; Bousquet, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-bdbb9092d97243bac1294c4fc1dcc7a729768db3071fb671d853d682368e95e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Physiological Phenomena</topic><topic>Drug therapy</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart</topic><topic>Humans</topic><topic>Hypertension - blood</topic><topic>Imidazoles - immunology</topic><topic>Imidazoles - metabolism</topic><topic>Imidazoline Receptors</topic><topic>Medical research</topic><topic>Receptors, Drug - immunology</topic><topic>Receptors, Drug - physiology</topic><topic>Vasomotor System - metabolism</topic><topic>Vasomotor System - physiopathology</topic><topic>Vertebrates: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dontenwill, M.</creatorcontrib><creatorcontrib>Tibiriça, E.</creatorcontrib><creatorcontrib>Greney, H.</creatorcontrib><creatorcontrib>Bennaï, F.</creatorcontrib><creatorcontrib>Feldman, J.</creatorcontrib><creatorcontrib>Stutzmann, J.</creatorcontrib><creatorcontrib>Bricca, G.</creatorcontrib><creatorcontrib>Belcourt, A.</creatorcontrib><creatorcontrib>Bousquet, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dontenwill, M.</au><au>Tibiriça, E.</au><au>Greney, H.</au><au>Bennaï, F.</au><au>Feldman, J.</au><au>Stutzmann, J.</au><au>Bricca, G.</au><au>Belcourt, A.</au><au>Bousquet, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of imidazoline receptors in cardiovascular regulation</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1994-12-22</date><risdate>1994</risdate><volume>74</volume><issue>13</issue><spage>A3</spage><epage>A6</epage><pages>A3-A6</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>The involvement of nonadrenergic imidazoline specific receptors in the central control of the vasomotor tone and in the mechanism of action of drugs bearing an imidazoline structure, or analogs, is now well documented. Imidazoline-specific binding sites were found in many tissues and species. Moreover, until now, it is only in the brainstem that such binding sites are associated with a function: the hyportensive effect of imidazoline-like drugs. Rilmenidine, which is an oxazoline structurally related to the reference imidazolines, exerts a central hypotensive effect of central origin involving imidazoline receptors. The selectivity of rilmenidine for the imidazoline receptors compared to
α
2-adrenergic receptors could explain the low incidence of sedative side effects observed with this antihypertensive drug. A specific anti-imidazoline radioimmunoassay allowed us to detect the presence of an immunoreactive imidazoline-like substance in human sera. High levels of this immunoreactive substance are associated with high blood pressure in 20–30% of the hypertensive patients. This observation indicates that high levels of this immunoreactive substance in the serum can be associated with some kinds of primary hypertension. The cause-and-effect relation between these 2 phenomena has not yet been determined. This substance is in process of purification; it could be a candidate to be an endogenous ligand of the imidazoline receptors.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7998582</pmid><doi>10.1016/0002-9149(94)90035-3</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1994-12, Vol.74 (13), p.A3-A6 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76888918 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Biological and medical sciences Brain - drug effects Brain - metabolism Cardiovascular disease Cardiovascular Physiological Phenomena Drug therapy Fundamental and applied biological sciences. Psychology Heart Humans Hypertension - blood Imidazoles - immunology Imidazoles - metabolism Imidazoline Receptors Medical research Receptors, Drug - immunology Receptors, Drug - physiology Vasomotor System - metabolism Vasomotor System - physiopathology Vertebrates: cardiovascular system |
| title | Role of imidazoline receptors in cardiovascular regulation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20imidazoline%20receptors%20in%20cardiovascular%20regulation&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Dontenwill,%20M.&rft.date=1994-12-22&rft.volume=74&rft.issue=13&rft.spage=A3&rft.epage=A6&rft.pages=A3-A6&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/0002-9149(94)90035-3&rft_dat=%3Cproquest_cross%3E4486781%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230351667&rft_id=info:pmid/7998582&rft_els_id=0002914994900353&rfr_iscdi=true |